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Rapid detection of tetracycline 
resistance in bovine Pasteurella 
multocida isolates by MALDI 
Biotyper antibiotic susceptibility 
test rapid assay (MBT-ASTRA)
Laura Van Driessche1, Jade Bokma1, Linde Gille  1, Pieter-Jan Ceyssens2, Katrin Sparbier3, 
Freddy Haesebrouck  4, Piet Deprez1, Filip Boyen4 & Bart Pardon1
Pasteurella multocida is notorious for its role as an opportunistic pathogen in infectious 
bronchopneumonia, the economically most important disease facing cattle industry and leading 
indication for antimicrobial therapy. To rationalize antimicrobial use, avoiding imprudent use of 
highly and critically important antimicrobials for human medicine, availability of a rapid antimicrobial 
susceptibility test is crucial. The objective of the present study was to design a MALDI Biotyper 
antibiotic susceptibility test rapid assay (MBT-ASTRA) procedure for tetracycline resistance detection 
in P. multocida. This procedure was validated on 100 clinical isolates with MIC-gradient strip test, and 
a comparison with disk diffusion was made. Sensitivity and specificity of the MBT-ASTRA procedure 
were 95.7% (95% confidence interval (CI) = 89.8–101.5) and 100% (95% CI = 100–100), respectively, 
classifying 98% of the isolates correctly after only three hours of incubation. Sensitivity and specificity 
of disk diffusion were 93.5% (95% CI = 86.3–100.6) and 96.3% (95% CI = 91.3–101.3) respectively, 
classifying 95% of the isolates correctly. In conclusion, this MBT-ASTRA procedure has all the potential 
to fulfil the need for a rapid and highly accurate tetracycline susceptibility testing in P. multocida to 
rationalize antimicrobial use in outbreaks of bronchopneumonia in cattle or other clinical presentations 
across species.
Pasteurella multocida, a Gram-negative coccobacillus, causes many important diseases in a wide range of hosts1. 
In different ruminant species and pigs it is one of the most frequently isolated pathogens in infectious broncho-
pneumonia2,3, a disease which is the leading cause of morbidity and antimicrobial use in these species4. In more 
tropical regions of the world, especially Africa and Asia, P. multocida can also cause highly fatal hemorrhagic 
septicemia in cattle and buffaloes5. In other animal species, this bacterium has been associated with presentations 
like sepsis6, but also otitis7 and peritonitis8. In humans, P. multocida can cause several life-threatening conditions, 
like sepsis9 and endocarditis10.
Today, to control bronchopneumonia mass medication is still one of the preferred therapies in different 
food-producing animal species4,11,12. Given the issue of high level antimicrobial resistance in these industries 
and the one health initiatives founded to combat this13–15, preventative antimicrobial use is no longer consid-
ered appropriate and antimicrobial treatment should be targeted16. In several European countries like Belgium, 
Germany or the Netherlands, guidelines suggest and legislation requires sampling and susceptibility testing 
of animal pathogens before specific antimicrobial agents can be used17–23. In addition, formularies have been 
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initiated in several countries to guide veterinarians to select appropriate antimicrobials mainly based on their 
clinical efficacy and importance for human medicine24,25. Especially in more intensive cattle rearing systems 
which rely on mass medication, antimicrobial multiresistance in P. multocida is common, hampering empiric 
antimicrobial therapy12,26–28. Multiresistant isolates, that compromise 12 antimicrobial resistance genes, are 
threatening the future of these production systems29.
To date, mainly disk diffusion susceptibility tests are used in veterinary practice to guide antimicrobial ther-
apy. These take a minimum of 2 days after sampling before results are available, but in most cases, due to different 
practical reasons, a waiting period of 3–4 days is average. In most outbreaks of infectious bronchopneumonia 
postponing an appropriate therapy, until susceptibility testing results are available, is not acceptable for economic 
and animal welfare reasons. On the other hand initiation of an inappropriate antibiotic treatment will increase 
antimicrobial resistance selection pressure30. Disk diffusion susceptibility tests have shown a sensitivity of only 
85.7% for the detection of tetracycline resistance in P. multocida compared to the agar dilution technique as the 
gold standard in the past31, which might result to therapeutic failure in practice. The agar dilution technique is 
however not commonly used in routine veterinary diagnostics, being a more laborious and expensive technique 
compared with disk diffusion. Although the antimicrobial gradient strip method is not regarded as the gold 
standard like the broth dilution technique currently, results achieved by both tests have a good correlation32–34. 
Other advantages of the antimicrobial gradient strip test are the ease of use in combination with reliability and 
interpretability, resulting in a simple, near gold standard test. Since previous studies regarding new diagnostic 
techniques use this method for diagnostic accuracy, this was also performed as reference test in the current study.
Guidance of antimicrobial therapy in food animals is urgently needed, especially given the dense popula-
tions and potentially high disease incidences in the current production systems. Latter results in exposure of 
many animals, their bacteria and environment to antimicrobial selection pressure. To support veterinarians in 
their decision making process for antimicrobial therapy, not only highly accurate, but especially rapid diagnostic 
Figure 1. Comparison of CAMHB (A) and BHIB (B) medium and different P. multocida starting 
concentrations to optimize bacterial growth to allow identification in an MBT-ASTRA procedure. Presented 
spectra are representative for the repetitions made using a single P. multocida isolate (P114, MIC: 0.19 µg/mL).
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procedures are crucial. This to avoid unnecessary production loss, animal suffering or antimicrobial selection 
pressure.
The MALDI Biotyper antibiotic susceptibility test rapid assay (MBT-ASTRA) method, a MALDI-TOF 
MS-based approach for susceptibility testing, characterized by a semi-quantitative measurement of bacterial pro-
teins, has shown promising results in obtaining rapid antimicrobial susceptibility results for human pathogens35. 
For some fast growing bacteria involved in sepsis in humans only 1–4 hours are needed for susceptibility test-
ing35–38. Also for slow growers like mycobacteria this method seems viable39. Furthermore, this technique shows 
a high sensitivity and specificity compared to minimum inhibitory concentration (MIC)-gradient strip test35–38. 
The potential of MBT-ASTRA for veterinary indications, especially those associated with mass medication, 
has not been explored. Furthermore applying this method on fastidious growers like P. multocida or any other 
Pasteurellaceae has not yet been described.
Therefore, the primary objective of the present study was to design and validate an MBT-ASTRA procedure for 
tetracycline resistance detection in P. multocida from bovine origin. The secondary objective was to determine diag-
nostic accuracy of this MBT-ASTRA procedure and classic disk diffusion compared to MIC-gradient strip testing.
Results
Determination of standard testing conditions for MBT-ASTRA. To determine the optimal growth 
medium and starting concentration of the bacterial suspension, one susceptible isolate (P114: MIC: 0.19 µg/mL) 
was incubated in two different media using three different starting concentrations for incubation times varying 
between 0 and 6 hours (Fig. 1). This experiment was repeated two times. No difference in growth, expressed by 
Figure 2. Area under the curve (AUC) (A) and Relative Growth (RG) (B) box plots of 3 susceptible and 
3 resistant P. multocida isolates after 3 hours of incubation without antibiotic (=ZER) or with 4 µg/mL of 
tetracycline (=FOU). For resistant strains, no clear difference between both AUCs is noticed and RGs are high, 
whereas susceptible strains obtain a lower RG. The horizontal red line represents a RG cut-off value of 0.5.
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the area under the curve (AUC), was seen between Cation-adjusted Mueller Hinton broth (CAMHB) and Brain 
Heart Infusion broth (BHIB) (Fig. 1). Starting concentration clearly affected growth, reaching sufficient bacte-
rial growth for MALDI-TOF identification after 6, 2–4 and 0 h with 1.5 × 106 CFU/mL, 1.5 × 107 CFU/mL and 
1.5 × 108 CFU/mL, respectively (Fig. 1).
Second, the antibiotic concentration allowing a clear separation between resistant and susceptible isolates was 
determined. To obtain this value, three susceptible (P114; MIC 0.19 µg/mL, P103; MIC 0.25 µg/mL and P113; 
MIC 0.5 µg/mL) and three resistant (P47; MIC 16 µg/mL, P162; MIC 24 µg/mL and P98; MIC 48 µg/mL) isolates 
of P. multocida were tested with tetracycline concentrations of 0, 2, 4 and 8 µg/mL and were incubated for 0, 3, 
4, 5 and 6 hours. This experiment was performed 3 times independently, each using 1 resistant and 1 susceptible 
strain. After incubation, the growth derived from an increased protein signal of these isolates was calculated by 
measuring the AUC of the obtained spectrum. In the susceptible isolates, the AUC of the sample with antibiotic 
should be significantly reduced in comparison with the sample without antibiotic. For resistant isolates, no sig-
nificant difference in AUC should be noticed. The relative growth (RG) ratio is the ratio of the AUC derived from 
spectra with and without antibiotic and is used to distinguish susceptible from resistant isolates according to an 
empirical cut-off value. A clear visual difference between susceptible and resistant isolates was achieved at a tetra-
cycline concentration of 4 µg/mL and a RG cut-off value of 0.5 (Fig. 2). In this preliminary test, the three resistant 
isolates showed a RG > 0.5, while the susceptibile isolates showed a RG < 0.5. A correct classification of all strains 
was already possible after 3 hours of incubation with 4 µg/mL tetracycline (Fig. 2).
Determination of the diagnostic accuracy of the MBT-ASTRA procedure and comparison with 
the disk diffusion method. MIC distribution of the study population. A total of 100 clinical P. multocida 
isolates were used to validate the MBT-ASTRA with the MIC-gradient strip test as reference test used in the 
current study. Of the isolates tested, 54 and 46 were classified as susceptible or resistant by MIC-gradient strip 
test, respectively. This experiment was conducted once. Tetracycline MIC-values for the quality control reference 
strains were tested twice and were in the acceptable range according to CLSI standards40, i.e. Staphylococcus 
aureus ATCC 29213 MIC-value 0.38 µg/mL and 0.5 µg/mL (range 0.12–1 µg/mL), Escherichia coli ATCC 25922 
MIC-value 0.5 µg/mL and 1.5 µg/mL (range 0.5–2 µg/mL) and Enterococcus faecalis ATCC 29212 MIC-value 
16 µg/mL (range 8–32 µg/mL). The tested isolates showed a bimodal MIC distribution, ranging between 0.094 
and 48 µg/mL (Fig. 3). According to veterinary CLSI standards40, P. multocida isolates are considered responsive 
to treatment (=susceptible) with tetracycline in cattle when they show an MIC value ≤ 2 µg/mL.
Diagnostic accuracy of MBT-ASTRA and disk diffusion. The MBT-ASTRA procedure was conducted for 100 
clinical isolates with an incubation time of 3 hours, with and without a tetracycline concentration of 4 µg/mL in 
CAMHB. This test was performed once. Relative growth values were determined for all tested isolates. Receiver 
operating characteristics (ROC) curve analysis showed a relative growth value of 0.5 to be the optimal cut-off to 
differentiate resistant from susceptible isolates for this MBT-ASTRA method (Fig. 4).
For the disk diffusion tests, quality control reference strains were included and inhibition zones (in mm) were 
in the acceptable range according to CLSI standards40, i.e. Staphylococcus aureus ATCC 25923 inhibition zone 
24 mm (range 24–30 mm) and Escherichia coli ATCC 25922 inhibition zone 22 mm (range 18–25 mm). The disk 
diffusion method with quality control reference strains included was performed once.
Table 1 shows classification of the test results of both MBT-ASTRA and disk diffusion compared to the 
MIC-gradient strip test. At a RG cut-off value of 0.5, a correct classification of all 54 susceptible strains and 95.7% 
Figure 3. MIC values for tetracycline of 100 recent clinical isolates of P. multocida used to determine 
diagnostic accuracy of an MBT-ASTRA procedure for this antimicrobial-bacterium combination. MIC values 
were determined by the MIC-gradient strip test. The vertical line represents the CLSI clinical breakpoint for 
susceptibility (≤2 µg/mL)40.
www.nature.com/scientificreports/
5ScIentIFIc REPORTS |  (2018) 8:13599  | DOI:10.1038/s41598-018-31562-8
(44/46) of resistant strains was achieved. All susceptible isolates showed RG values smaller than 0.5. All resistant 
isolates had RG values above 0.5, except two isolates (P33, P106) with an MIC value of 6 µg/mL that showed a RG 
value of 0.34 and 0.25 respectively, causing 2 false susceptible results (Fig. 4).
Diagnostic accuracy of the disk diffusion and MBT-ASTRA method was calculated using the MIC-gradient 
strip test as reference (Table 2). Compared to MIC-gradient strip testing, the MBT-ASTRA method achieved a 
sensitivity and specificity of 95.7% and 100%, respectively. Sensitivity and specificity of disk diffusion were 93.5% 
and 96.3%, respectively. The essential agreement of MBT-ASTRA with the MIC-gradient strip test is 98%, due to 
2% very major errors (Table 2). In contrast, the disk diffusion method obtained an essential agreement of 95%, 
including 3% very major errors and 2% major errors (Table 2).
Discussion
This study aimed at developing a MALDI-TOF MS-based approach for rapid tetracycline susceptibility testing 
in P. multocida and to compare this technique and the current standard test in practice (disk diffusion) with the 
MIC-gradient strip test. The most widely accepted gold standard for susceptibility testing in bacteria is the broth 
dilution technique41,42. In order to compare the obtained data with previous studies, which commonly used the 
MIC-gradient strip test, the authors also opted for MIC-gradient strip testing35–38. MIC-gradient strip test results 
have a good correlation with MIC values achieved by broth dilution technique, and is often considered as a near 
gold standard test32–34. Therefore, the authors believe that current results based on the MIC-gradient strip test 
will hardly differ from broth dilution results. Further research can include latter technique as gold standard for 
determining the accuracy of the MBT-ASTRA method.
Another limitation was that no intermediate results were obtained from neither techniques. In practice, 
to avoid therapeutic failure, intermediate results are often regarded as resistant, and another antimicrobial is 
selected. As the MBT-ASTRA method is currently unable to correctly classify intermediate susceptibility iso-
lates for a given antibiotic, including isolates with intermediate results on the reference test would have been an 
added value. Unfortunately, no isolates classified as intermediate by MIC-gradient strip test were obtained in 
Figure 4. Scatter plot of minimum inhibitory concentrations (MIC) obtained with the MIC-gradient strip 
test with MBT-ASTRA relative growth (RG) values of 100 recent bovine clinical strains of P. multocida. MBT-
ASTRA testing conditions were 3 hours of incubation with a concentration of tetracycline of 4 µg/mL. The 
horizontal and vertical line represent the clinical breakpoint of ≤2 µg/mL and the RG cut-off value of 0.5, 
respectively. Two isolates with an MIC value of 6 µg/mL are considered susceptible with MBT-ASTRA, causing 2 
false susceptible results.
Test
Reference test (MIC-gradient strip test)
Resistant Susceptible
MBT-ASTRA
Resistant 95.7% (44/46) 0% (0/54)
Susceptible 4.3% (2/46) 100% (54/54)
Total 100% (46/46) 100% (54/54)
Disk diffusion
Resistant 93.5% (43/46) 3.7% (2/54)
Susceptible 6.5% (3/46) 96.2% (52/54)
Total 100% (46/46) 100% (54/54)
Table 1. 2 × 2 Contingency table showing tetracycline resistance testing results of MBT-ASTRA and disk 
diffusion compared to MIC-gradient strip test for 100 recent clinical P. multocida isolates derived from cattle.
www.nature.com/scientificreports/
6ScIentIFIc REPORTS |  (2018) 8:13599  | DOI:10.1038/s41598-018-31562-8
this study. Also in previous work, this has not been accounted for36,37. Modifications to this method that would 
allow classification of intermediate include correlations between the relative growth and MIC value and by using 
a serial dilution of the given antibiotic to define an MBT-ASTRA minimal breakpoint37. However, classification 
as intermediate is contra productive for clinical decision making and may lead to more inappropriate treatments.
The main conclusion of the present study is that the MBT-ASTRA method allows for a tetracycline susceptibil-
ity testing result for P. multocida in only three hours of incubation with high accuracy. This incubation time is in 
the same range compared to the MBT-ASTRA method for fast growing bacteria involved in sepsis in humans35–38. 
Although P. multocida is considered a fastidiously growing microorganism by CLSI40 and tetracycline is con-
sidered bacteriostatic, which might cause a longer incubation time to obtain a clear difference in AUC with or 
without antibiotic. Due to this short incubation period, the MBT-ASTRA method makes it possible to provide 
the results of the susceptibility test on the same day of identification, avoiding unnecessary production loss or 
animal suffering. Sensitivity (95.7%) and specificity (100%) of the presented MBT-ASTRA procedure were exces-
sive, in the range of and even higher than compared to previous findings applying MBT-ASTRA for other species 
under different conditions35–38. In contrast, the disk diffusion method evaluated in this study had lower sensitivity 
(93.5%) and specificity (96.3%). A previous study on P. multocida isolates showed lower sensitivity (85.7%) and 
higher specificity (99.1%) of disk diffusion for tetracycline resistance detection31. A possible explanation for this 
difference could be that at that time disks with higher tetracycline contents (80 µg) were used and clinical break-
points differed with those obtained in the current study. Classification of the 100 isolates with disk diffusion was 
performed using the interpretative criteria of the manufacturer’s guidelines. Currently, no P. multocida-specific 
clinical breakpoints for tetracycline in cattle are available for disk diffusion, while they are described for MIC 
testing40. Zone diameters (mm) were measured and analysed. A clear difference between susceptible (zone diam-
eter ranging from 24–32 mm) and resistant (zone diameter ranging from 8–10 mm) isolates was noticed. Due to 
these considerable differences in zone diameter, modifying the clinical breakpoints would have little to no effect 
on the results.
Compared to the disk diffusion method as used under the current circumstances, MBT-ASTRA shows less 
discrepancies to the MIC-gradient strip test method. However, in 2% of the isolates tested a very major error was 
present, potentially resulting in treatment of the animal with tetracycline when the isolate is resistant. Both of 
these isolates had an MIC value of 6 µg/mL. According to CLSI standards, an MIC value of 4 µg/mL is classified as 
intermediate and an MIC value ≥ 8 µg/mL is classified as resistant. Considering these clinical breakpoints, both 
strains with an MIC value of 6 µg/mL can be classified as (borderline) resistant, resulting in 2% very major errors 
and a sensitivity of 95.7% with the MBT-ASTRA method. However, the clinical outcome of treatment with tetra-
cycline of P. multocida isolates with an MIC value of 6 µg/mL might be difficult to distinctly predict.
Given its rapid results and high diagnostic accuracy, this MBT-ASTRA technique has high potential to be 
used in the field as a decision aid to direct antimicrobial use in food animals. In order to fulfil this potential, the 
possibilities of obtaining a full susceptibility test (as many antimicrobials tested at once as in disk diffusion) need 
to be explored, and the practical issue of availability of a MALDI-TOF MS in the regional laboratories needs to 
be overcome. However, in recent years the use of MALDI-TOF MS has been advanced to a standard method 
in clinical microbiology laboratories, due to its rapid and low-cost characteristics43. Considering the simple 
Disk diffusion MBT-ASTRA
Essential agreement 95% 98%
Very major error 3% 2%
Major error 2% 0%
Minor error 0% 0%
Sensitivity
93.5% 95.7%
(86.3%, 100.6%) (89.8%, 101.5%)
Specificity
96.3% 100%
(91.3%, 101.3%) (100.0%, 100.0%)
RPV
95.6% 100%
(89.5%, 101.6%) (100.0%, 100.0%)
SPV
94.5% 96.4%
(88.5%, 100.5%) (91.6%, 101.3%)
Table 2. Diagnostic accuracy of disk diffusion and MBT-ASTRA for tetracycline susceptibility testing in 100 
clinical P. multocida isolates from cattle compared to the MIC-gradient strip test. Values between brackets 
represent the 95% confidence interval of the estimate. Definitions describing the diagnostic accuracy31,47,48. 
Essential agreement: results of both techniques identical; very major: resistant strain by the MIC-gradient strip 
test method misinterpreted as susceptible by disk diffusion/MBT-ASTRA; major: susceptible strain by the MIC-
gradient strip test method misinterpreted as resistant by disk diffusion/MBT-ASTRA; minor error: intermediate 
result was obtained by only one method; sensitivity is number of resistant strains by disk diffusion or MBT-
ASTRA/number of resistant strains by MIC-gradient strip test; specificity is number of susceptible strains 
by disk diffusion or MBT-ASTRA/number of susceptible strains by MIC-gradient strip test. RPV, resistant 
(positive) predictive value; the probability that a strain is truly resistant if the disk diffusion method or MBT-
ASTRA categorizes a strain as resistant; SPV, susceptible (negative) predictive value is defined as the probability 
that a strain is truly susceptible if the disk diffusion method or MBT-ASTRA categorizes a strain as susceptible.
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setup and short incubation time, the MBT-ASTRA method implements an early intervention of adequate anti-
biotic therapy, resulting in a cost-and –labour efficient tool like the disk diffusion method. Whether the current 
MBT-ASTRA settings are also applicable to other Pasteurellaceae of clinical importance in veterinary medicine, 
like Mannheimia haemolytica or Histophilus somni, needs to be determined.
In conclusion, the MBT-ASTRA method developed in the present study, has all the potential to fulfil the need 
for a rapid and highly accurate tetracycline susceptibility testing in P. multocida. This is essential to rationalize 
antimicrobial use in outbreaks of bronchopneumonia in cattle or other clinical presentations across species.
Methods
Determination of the standard conditions for MBT-ASTRA. Selection of the optimal growth medium 
and starting concentration of P. multocida. BHIB (Difco, BD Diagnostic Systems, Sparks, Md.) and CAMHB 
(Difco, BD Diagnostic Systems, Sparks, Md.) were used as growth media in this study. One susceptible strain of 
P. multocida (P114, MIC 0.19 µg/mL) was inoculated in 10 mL of BHIB or 10 mL of CAMHB at different starting 
concentrations. Starting concentrations tested in both media were 1.5 × 106 CFU/mL, 1.5 × 107 CFU/mL and 
1.5 × 108 CFU/mL. No antibiotics were added to the medium. All tubes were placed in a shaking incubator for 0, 
1, 2, 3, 4 and 6 hours at a temperature of 37 °C and an atmosphere enriched with 5% CO2. After each incubation 
period, 1 mL samples of each tube were transferred to Eppendorf tubes.
Selection of the optimal tetracycline concentration and incubation time. To determine the optimal concentration of 
tetracycline and the shortest incubation time necessary to differentiate between susceptible and resistant isolates, 
three susceptible isolates (P114; MIC 0.19 µg/mL, P103; MIC 0.25 µg/mL, P113; MIC 0.5 µg/mL) and three resistant 
isolates (P47; MIC 16 µg/mL, P162; MIC 24 µg/mL and P98; MIC 48 µg/mL) were used. Tetracycline concentrations 
of 0, 2, 4 and 8 µg/mL were tested (Sigma-Aldrich, Germany) at incubation periods of 0–3–4–5 and 6 hours.
MBT-ASTRA sample preparation. Eppendorf tubes, containing 1 mL samples grown for the indicated incubation 
time, were centrifuged at 21130 × g for 5 minutes at room temperature. After centrifugation, the supernatant was 
carefully aspirated and 700 µL of 70% ethanol in high performance liquid chromatography (HPLC) graded water 
was added to the cell pellet and vortexed. A second centrifugation and aspiration of the supernatant was performed 
as mentioned above. After air drying for a minimum of 10 minutes, the cell pellets were stored at −20 °C for up to 
a maximum of 3 days. After storing, 20 µL 70% formic acid (in HPLC graded water) was added to the cell pellet 
and mixed carefully. Samples were incubated for five minutes at room temperature. In a last step, 20 µL of acetoni-
trile was added and vortexed. Before adding acetonitrile to the cell pellet, an internal standard35 (Bruker Daltonik 
GmbH, Bremen, Germany, suspended in 25 µL HPLC water) was added to acetonitrile (ratio of 1/100, using 0.2 µL 
of internal standard in 20 µL of acetonitrile per sample) for spectra acquisition and facilitating the semi-quantitative 
analysis of the acquired spectra to quantify the difference in biomass corresponding to the growth between differ-
ent setups. A third centrifugation step (21130 × g for 2 minutes) was performed to clarify the lysates.
MALDI-TOF MS analysis. One µL of the protein extraction was spotted in triplicate on the target plate (MSP 96 
target polished steel BC). After air drying of the spots, 1 µl of matrix (10 mg/ml of α-cyano-4-hydroxy-cinnamic 
acid [α-HCCA] in 50% acetonitrile - 47.5% water - 2.5% trifluoroacetic acid; Bruker Daltonik GmbH, Bremen, 
Germany) was placed on each spot. External calibration was included in each measurement using a bacterial 
test standard (BTS, Bruker Daltonik GmbH, Bremen, Germany). Analysis was performed with an Autoflex III 
smartbeam MALDI-TOF MS instrument (Bruker Daltonik GmbH, Bremen, Germany), recording the mass range 
between 2.000–20.000 Da using standard settings. Automated data analysis was performed with the MBT-ASTRA 
software prototype written in the software package R35. A mass range of 2.500–13.500 was used for analysis. AUC 
and relative growth rate were calculated automatically for each setup. The duration of MALDI-TOF analysis is 
around 10–15 minutes for one sample. This duration is not cumulative when analysing multiple samples.
The obtained optimal test conditions were subsequently used during assay validation, analysing 100 recent 
clinical P. multocida isolates to determine the cut-off value of the relative growth ratio that allows a differentiation 
between susceptible and resistant isolates.
Determination of diagnostic accuracy of the MBT-ASTRA procedure and comparison with the 
disk diffusion method. Bacterial isolates and cultivation. In this experiment, 100 isolates of P. multo-
cida from calves with bronchopneumonia collected in Belgium between 2014 and 2017 were analysed. Sampling 
of these calves was performed using a deep nasopharyngeal swab or a broncho-alveolar lavage as previously 
described44. All methods were carried out in accordance with relevant guidelines and regulations. All experimen-
tal protocols were approved by the ethical committee of the Faculty of Veterinary Medicine, Ghent University (EC 
2014/164, EC 2016/20). Identification of P. multocida isolates was first achieved by standard biochemical tests45 
and subsequently confirmed with MALDI-TOF MS using the direct transfer protocol as previously described46. 
Bacteria were cultivated overnight at 37 °C and an atmosphere enriched with 5% CO2 on Columbia agar (Oxoïd, 
UK) supplemented with 5% sheep blood.
Three susceptibility testing methods were performed on all isolates, namely MIC-gradient strip test, which is 
comparable to the standard dilution test32–34, the MBT-ASTRA procedure as described above and disk diffusion 
as the current standard test in practice.
MIC-gradient strip test. The MIC values of tetracycline were determined using MIC-gradient strips. Briefly, 
MIC test strips (Liofilchem, Italy) were placed on Mueller Hinton agar plates enriched with 5% defibrinated 
sheep blood (BD Diagnostics Systems), shortly after the plates had been uniformly inoculated via polyester 
swabs with 0.5 McFarland suspensions of the pure isolates. Incubation was performed for 18–24 hours under 
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aerobic conditions at 35 °C. Staphylococcus aureus ATCC 29213 and Escherichia coli ATCC 25922 were used 
as quality control reference strains. MIC values were determined according to the manufacturer’s instructions. 
Determination of susceptibility was performed according to the current CLSI standards for bovine P. multocida 
(i.e. susceptible ≤2 µg/mL, intermediate 4 µg/mL, resistant ≥8 µg/mL)40. Used media, incubation conditions, 
quality control strains and used interpretive criteria were applied according to CLSI standards40. Inoculation 
method was performed according to manufacturer’s guidelines.
MBT-ASTRA procedure. All isolates were incubated for 3 hours with and without a tetracycline concentration 
of 4 µg/mL in CAMHB with a starting concentration of 1.5 × 107CFU/mL. MBT-ASTRA sample preparation and 
MALDI-TOF MS analysis were performed immediately after incubation as mentioned above.
Disk diffusion test. Susceptibility testing of P. multocida and tetracycline was performed in accordance with 
CLSI standards40. Briefly, Mueller Hinton agar (Oxoïd, UK) plates, supplemented with 5% sheep blood, were 
uniformly inoculated via polyester swabs with 0.5 McFarland suspensions of the pure isolates. Then, tetracy-
cline disks (30 µg/mL, Rosco, Neosensitabs, Taarstrup, Denmark) were placed on Mueller Hinton agar (Oxoïd, 
UK) supplemented with 5% sheep blood, shortly after the plates had been uniformly inoculated via polyester 
swabs with 0.5 McFarland suspensions of the pure isolates. Incubation was performed for 18–24 hours at 35 °C 
in ambient air. Analysis of inhibition zones (in mm) was performed and interpretative criteria were according 
to manufacturer’s guidelines. Staphylococcus aureus ATCC 25923 and Escherichia coli ATCC 25922 were used as 
quality control reference strains.
Statistical analysis. Receiver operating characteristics (ROC) curve analysis was used to determine the optimal 
cut-off of the relative growth ratio to distinguish resistant from susceptible isolates in the MBT-ASTRA proce-
dure (SPSS statistics vs. 24 (IBM, New York, United States)). Performance of the MBT-ASTRA and disk diffusion 
method compared to the MIC-gradient strip test as the gold standard was determined. Results were presented by 
distinguishing very major (resistant strain by the MIC-gradient strip test method misinterpreted as susceptible 
by the disk diffusion/MBT-ASTRA method), major (susceptible strain by the MIC-gradient strip test method 
misinterpreted as resistant by the disk diffusion/MBT-ASTRA method) and minor errors (intermediate result 
was obtained by only one method)31,47,48. Diagnostic accuracy, sensitivity, specificity, RPV and SPV were derived 
from 2 × 2 contingency tables using Winepiscope 2.049.
Availability of Data and Materials
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